Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 7 points (0.0%) at 16,563 as of Tuesday, Aug. 12, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,349 issues advancing vs. 1,605 declining with 179 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Abbott Laboratories ( ABT), down 1.2%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.1%, HCA Holdings ( HCA), down 0.7%, St Jude Medical ( STJ), down 0.6% and Aetna ( AET), down 0.5%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.6%, Intuitive Surgical ( ISRG), up 1.4%, WellPoint ( WLP), up 0.9%, Cigna ( CI), up 0.8% and Boston Scientific ( BSX), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.31 (-0.9%) to $35.21 on light volume. Thus far, 214,326 shares of Grifols exchanged hands as compared to its average daily volume of 705,700 shares. The stock has ranged in price between $34.83-$35.45 after having opened the day at $35.42 as compared to the previous trading day's close of $35.52. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $12.2 billion and is part of the health care sector. Shares are down 1.7% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, robust revenue growth, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.